Design and rationale of a randomized study to compare amiodarone and Class IC anti-arrhythmic drugs in terms of atrial fibrillation treatment efficacy in patients paced for sinus node disease: the PITAGORA trial.
OBJECTIVE
Many sinus node disease (SND) patients suffer from atrial fibrillation (AF). Anti-arrhythmic drugs (AADs) are the therapeutic mainstay for AF prophylaxis. The PITAGORA trial has a multicentre, prospective, randomized, single blind design to compare amiodarone with Class IC AADs in patients who have an AF history and are paced for SND.


RESULTS
Starting from January 2001, 176 patients received a Medtronic AT500 pacemaker. AADs were randomly assigned with a 3 : 2 ratio between Class III and Class IC. Randomization was stratified in order to assign two patients to amiodarone and one patient to sotalol every three Class III AAD patients. After a 5-month observational period, Ramp or Burst+ ATP therapies were enabled in a randomized way, maintained for 4 months, and then crossed over. Total follow-up period is 21 months. The primary long-term objective is to show the non-inferiority of IC AADs compared with amiodarone in terms of time to first occurrence of a composite endpoint (death, atrial cardioversion, hospitalizations due to AF or heart failure, or change of AADs). Data will be analysed on an intention-to-treat basis. The primary short-term objective is to compare Ramp vs. Burst+ efficacy in terminating atrial tachyarrhythmias treated by the device. Secondary endpoints are major clinical events, medication toxicity, symptoms, AF burden, and quality-of-life.


CONCLUSIONS
Given the high morbidity and healthcare costs associated with AF, new therapeutic strategies are needed. The results of the PITAGORA trial may help in guiding AADs therapy and ATP programming in SND patients suffering from AF.
Gulizia
Michele
M
Cardiology Department, Garibaldi-Nesima Hospital, Via Palermo 636, Catania, 95122, Italy. michele.gulizia@tin.it
Mangiameli
Salvatore
S
Chiarandà
Giacomo
G
Spadola
Vincenzo
V
Di Giovanni
Nicolò
N
Colletti
Andrea
A
Bulla
Vincenzo
V
Circo
Antonio
A
Pensabene
Orazio
O
Vasquez
Ludovico
L
Vaccaro
Ignazio
I
Grammatico
Andrea
A
D000638:Amiodarone / Q000627:therapeutic use*; D000889:Anti-Arrhythmia Agents / Q000627:therapeutic use*; D001146:Arrhythmia, Sinus / Q000628:therapy*; D001281:Atrial Fibrillation / Q000188:drug therapy*; D002304:Cardiac Pacing, Artificial; D005260:Female; D006801:Humans; D007558:Italy; D008297:Male; D011446:Prospective Studies; D012107:Research Design; D011795:Surveys and Questionnaires; D016896:Treatment Outcome
D000889:Anti-Arrhythmia Agents; D000638:Amiodarone